Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 04 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 5 pages · English

Summary by 6ix AI

This acquisition is aimed at enhancing Zydus's portfolio for treating rare diseases, specifically Hutchinson-Gilford Progeria Syndrome. The press release details the significance of Zokinvy as the first FDA-approved treatment for this ultra-rare genetic condition. The acquisition was finalized following a court-approved sale process, with Sentynl Therapeutics, a subsidiary of Zydus, acquiring global rights to Zokinvy.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 04, 2024, titled "Sentynl Therapeutics announces global acquisition of Zokinvy�� (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases